159938 医药
已收盘 03-11 15:00:00
资讯
新帖
简况
中国银河证券：医保省级统筹或成医药中长期投资新起点 医疗服务、创新药等板块值得关注
智通财经 · 14:10
中国银河证券：医保省级统筹或成医药中长期投资新起点 医疗服务、创新药等板块值得关注
欧康医药（920230）披露董事会秘书及财务负责人任命公告，3月10日股价上涨0.32%
证券之星 · 03-10 22:47
欧康医药（920230）披露董事会秘书及财务负责人任命公告，3月10日股价上涨0.32%
华昊中天医药董事长唐莉：优化创新药研发体系 助推产业高质量发展
每日经济新闻 · 03-10 22:46
华昊中天医药董事长唐莉：优化创新药研发体系 助推产业高质量发展
智通港股解盘 | 特朗普踩刹车全球股市反弹积极 科技和医药率先修复
智通财经 · 03-10 19:20
智通港股解盘 | 特朗普踩刹车全球股市反弹积极 科技和医药率先修复
长江生命科技(00775)宣布成立顺谱医药科技有限公司 专注推动旗下治疗性癌症疫苗组合的发展
智通财经 · 03-10 16:57
长江生命科技(00775)宣布成立顺谱医药科技有限公司 专注推动旗下治疗性癌症疫苗组合的发展
3月10日爱迪特涨8.62%，银河医药混合A基金重仓该股
证券之星 · 03-10 16:29
3月10日爱迪特涨8.62%，银河医药混合A基金重仓该股
3月10日泽璟制药涨7.24%，汇添富创新医药混合A基金重仓该股
证券之星 · 03-10 16:21
3月10日泽璟制药涨7.24%，汇添富创新医药混合A基金重仓该股
港股通标的调整落地，医疗医药板块分化明显
21世纪经济报道 · 03-10 11:59
港股通标的调整落地，医疗医药板块分化明显
和黄医药紧急宣布召回一款重磅肿瘤创新药；英硅智能与Liquid AI发布轻量科研基础模型 | 医药早参
每日经济新闻 · 03-10 07:09
和黄医药紧急宣布召回一款重磅肿瘤创新药；英硅智能与Liquid AI发布轻量科研基础模型 | 医药早参
国家医保局：3月9日起撤销氢溴酸他泽司他片在全国各省级医药采购平台挂网
人民财讯 · 03-09 18:58
国家医保局：3月9日起撤销氢溴酸他泽司他片在全国各省级医药采购平台挂网
港股异动 | 劲方医药-B(02595)涨超11% 公司将获纳入港股通 预计GFH375治疗结果将于国际学术会议发布
智通财经 · 03-09 09:57
港股异动 | 劲方医药-B(02595)涨超11% 公司将获纳入港股通 预计GFH375治疗结果将于国际学术会议发布
AI技术推动医药领域创新“加速跑”
经济参考网 · 03-06
AI技术推动医药领域创新“加速跑”
3月6日美诺华涨8.41%，富安达医药创新混合A基金重仓该股
证券之星 · 03-06
3月6日美诺华涨8.41%，富安达医药创新混合A基金重仓该股
港股异动 | 同源康医药-B(02410)涨超5% 公司完成H股全流通 艾多替尼上市申请获正式受理并纳入优先审评
智通财经网 · 03-06
港股异动 | 同源康医药-B(02410)涨超5% 公司完成H股全流通 艾多替尼上市申请获正式受理并纳入优先审评
中银港股通医药混合发起A基金经理变动：增聘王方舟为基金经理
证券之星 · 03-06
中银港股通医药混合发起A基金经理变动：增聘王方舟为基金经理
【券商聚焦】交银国际：医药公司业绩兑现有望催化板块行情
金吾财讯 · 03-06
【券商聚焦】交银国际：医药公司业绩兑现有望催化板块行情
德琪医药新药授权给优时比；司美格鲁肽治疗MASH拟纳入优先审评｜医药早参
每日经济新闻 · 03-05
德琪医药新药授权给优时比；司美格鲁肽治疗MASH拟纳入优先审评｜医药早参
34岁潮汕籍女掌门，拿下100亿医药大单
21世纪经济报道 · 03-05
34岁潮汕籍女掌门，拿下100亿医药大单
放弃百万年薪去读佛学！国联民生证券医药首席分析师郑薇离任：人生是随机盲盒，想做点真正想做的事
新浪证券 · 03-04
放弃百万年薪去读佛学！国联民生证券医药首席分析师郑薇离任：人生是随机盲盒，想做点真正想做的事
3月4日常山药业跌5.88%，医药LOF基金重仓该股
中金财经 · 03-04
3月4日常山药业跌5.88%，医药LOF基金重仓该股
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159938","market":"SZ","secType":"STK","nameCN":"医药","latestPrice":0.645,"timestamp":1773212601000,"preClose":0.646,"halted":0,"volume":27988400,"delay":0,"changeRate":-0.0015,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.001,"latestTime":"03-11 15:00:00","open":0.647,"high":0.647,"low":0.642,"amount":18037800,"amplitude":0.0077,"askPrice":0.645,"askSize":735,"bidPrice":0.644,"bidSize":1462,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773279000000},"marketStatusCode":5,"adr":0,"adjPreClose":0.646,"symbolType":"fund","openAndCloseTimeList":[[1773192600000,1773199800000],[1773205200000,1773212400000]],"highLimit":0.711,"lowLimit":0.581,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.152053,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159938","defaultTab":"news","newsList":[{"id":"2618915830","title":"中国银河证券：医保省级统筹或成医药中长期投资新起点 医疗服务、创新药等板块值得关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2618915830","media":"智通财经","labels":["economic"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618915830?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:10","pubTimestamp":1773209440,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，医保基金省级统筹推进提速，提升医保资金使用效率，有望成为医药投资新起点。通过推进省级统筹与个人账户跨省共济，有望盘活医保存量结余资金，有效破解医保收支结构性矛盾，扭转支出增速放缓趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","06881","06978","09939","161027","BK0188","BK1147","BK1515","159938","BK1564","BK1161","BK0276","601881","BK1574"],"gpt_icon":0},{"id":"2618951188","title":"欧康医药（920230）披露董事会秘书及财务负责人任命公告，3月10日股价上涨0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618951188","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618951188?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:47","pubTimestamp":1773154033,"startTime":"0","endTime":"0","summary":"截至2026年3月10日收盘，欧康医药报收于12.57元，较前一交易日上涨0.32%，最新总市值为12.66亿元。近日，成都欧康医药股份有限公司披露《高级管理人员任命公告》。公告显示，公司于2026年3月9日召开第四届董事会第十五次会议，审议通过聘任贾秀蓉女士为公司董事会秘书、李英女士为公司财务负责人的议案。任职期限自董事会审议通过之日起至第四届董事会任期届满，自2026年3月9日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000038730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1574","BK1161","09939","159938"],"gpt_icon":0},{"id":"2618269951","title":"华昊中天医药董事长唐莉：优化创新药研发体系 助推产业高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2618269951","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618269951?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:46","pubTimestamp":1773153961,"startTime":"0","endTime":"0","summary":"2026年是“十五五”开局之年，为推动生物医药产业在“十五五”期间实现高质量发展，我建议：进一步优化创新药审评审批流程，对临床急需的创新药设立优先通道，压缩药品从实验室到临床应用的时间周期。加大对肿瘤领域创新药研发的政策与资金扶持。加强“产学研医”协同机制，鼓励医疗机构与研发企业深度合作，建立高水平临床试验平台，整合优势资源，提升创新药研发效率与成功率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667812761.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667812761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","09939","06978","159938","BK1574","BK1515","BK1161"],"gpt_icon":0},{"id":"2618932267","title":"智通港股解盘 | 特朗普踩刹车全球股市反弹积极 科技和医药率先修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2618932267","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618932267?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:20","pubTimestamp":1773141651,"startTime":"0","endTime":"0","summary":"国际油价急速下跌，然后美股神奇反弹，全球股市也反弹积极，港股今天跳空涨2.17%。2，中期选举在即，没有结果的打下去，特朗普凶多吉少毫无胜算。鉴于特朗普一贯的出尔反尔，还是谨慎为妙。但伊朗的这个动作本身就凸显了其强硬和自信。今天市场反弹的主力是科技股，主要围绕“龙虾”，深圳市龙岗区后续又宣布，将于3月14日下午2:30在深圳机器人剧场举办“千人龙虾大会”。其中，全球最大吨位4000吨全地面起重机实现批量发货。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1171","SG9999006597.SGD","06613","01415","VT","HK0000320264.USD","BK1508","BK1504","IE0034224299.USD","VXUS","159938","02018","BK1515","BK1608","HK0000306701.USD","BK1548","BK1574","01157","HK0000320223.HKD","SG9999014674.SGD","02038","BK1505","BK1167","HK0000306685.HKD","BK1500","BK1161","BK1170","BK4588","BK1607","09939","BK4585"],"gpt_icon":0},{"id":"2618474938","title":"长江生命科技(00775)宣布成立顺谱医药科技有限公司 专注推动旗下治疗性癌症疫苗组合的发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2618474938","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618474938?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:57","pubTimestamp":1773133025,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长江生命科技 发布公告，宣布成立公司全资附属公司顺谱医药科技有限公司，专注推动旗下治疗性癌症疫苗组合的发展。公司成立 Sequencio，将旗下治疗性癌症疫苗研发项目整合至一个专注平台，充分体现公司锐意拓展此新兴癌症免疫疗法领域的策略方针。Sequencio 肩负长远愿景——重塑癌症治疗模式，从引导短暂性肿瘤缩小，迈向透过免疫系统达致长期可控的缓解。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","159938","BK1515","BK1574","09939","BK1161","00775","BK1569"],"gpt_icon":0},{"id":"2618498024","title":"3月10日爱迪特涨8.62%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618498024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618498024?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:29","pubTimestamp":1773131382,"startTime":"0","endTime":"0","summary":"证券之星消息，3月10日爱迪特涨8.62%，收盘报86.03元，换手率10.37%，成交量7.47万手，成交额6.34亿元。重仓爱迪特的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元，最新净值0.611，较上一交易日下跌0.38%，近一年上涨19.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000024680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","301580","09939","159938","BK0251","BK1515"],"gpt_icon":0},{"id":"2618980695","title":"3月10日泽璟制药涨7.24%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980695","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618980695?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:21","pubTimestamp":1773130879,"startTime":"0","endTime":"0","summary":"证券之星消息，3月10日泽璟制药涨7.24%，收盘报85.8元，换手率1.52%，成交量4.01万手，成交额3.41亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共84家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为72.69亿元，最新净值1.616，较上一交易日下跌1.67%，近一年上涨22.01%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000024253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK1515","BK1574","159938","09939","BK0239","BK1161"],"gpt_icon":0},{"id":"2618885419","title":"港股通标的调整落地，医疗医药板块分化明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2618885419","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618885419?lang=zh_cn&edition=full","pubTime":"2026-03-10 11:59","pubTimestamp":1773115164,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明3月10日早间，港股医疗医药板块部分个股开盘表现持续活跃。其中，英硅智能以61.45港元/股开盘，较昨日收盘价上涨3.36%；科济药业开盘价为14.44港元/股，涨幅达3.74%；劲方医药、维立志博、海西新药等多家企业亦呈现上涨态势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667267995.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667267995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159891","BK4585","BK1161","BK4588","159938","VXUS","BK1574","09939","BK1515"],"gpt_icon":0},{"id":"2618360871","title":"和黄医药紧急宣布召回一款重磅肿瘤创新药；英硅智能与Liquid AI发布轻量科研基础模型 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2618360871","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618360871?lang=zh_cn&edition=full","pubTime":"2026-03-10 07:09","pubTimestamp":1773097780,"startTime":"0","endTime":"0","summary":"｜2026年3月10日星期二｜NO.1和黄医药紧急宣布召回一款重磅肿瘤创新药3月9日晚间，和黄医药公告称，其氢溴酸他泽司他片（商品名：达唯珂）的合作方益普生（Ipsen）已通知和黄医药正在美国自愿撤市该药，因此已采取措施在中国启动撤市及产品召回程序。和黄医药已随即启动在内地、香港和澳门撤市并召回该产品，并停止所有正在进行中的达唯珂的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103666571762.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103666571762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK1515","HCM","BK1588","BK1587","BK4585","09939","06978","BK1191","BK1161","BK4531","BK1574","BK4007","BK4588","159992","00013"],"gpt_icon":0},{"id":"2618628800","title":"国家医保局：3月9日起撤销氢溴酸他泽司他片在全国各省级医药采购平台挂网","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628800","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618628800?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:58","pubTimestamp":1773053892,"startTime":"0","endTime":"0","summary":"人民财讯3月9日电，国家医保局办公室发布关于氢溴酸他泽司他片有关事项的通知称，3月9日，和黄医药（中国）有限公司发布公告，对其授权引进产品氢溴酸他泽司他片（商品名：达唯珂）启动撤市及产品召回程序。据此，自2026年3月9日起，撤销氢溴酸他泽司他片在全国各省级医药采购平台挂网，并根据企业申请，将氢溴酸他泽司他片移出《商业健康保险创新药品目录（2025年）》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666212644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK1515","09939","BK1161","BK1574"],"gpt_icon":0},{"id":"2618180316","title":"港股异动 | 劲方医药-B(02595)涨超11% 公司将获纳入港股通 预计GFH375治疗结果将于国际学术会议发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2618180316","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618180316?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:57","pubTimestamp":1773021454,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B涨超11%，截至发稿，涨9.96%，报27.6港元，成交额4006.33万港元。近日，劲方医药-B公告称，公司GFH375获得国内首个KRAS G12D抑制剂治疗非小细胞肺癌的突破性疗法认定。值得关注的是，GFH375治疗KRAS G12D突变型实体瘤及NSCLC的初步研究数据，曾在2025年登陆美国临床肿瘤学会年会及世界肺癌大会的突破性研究摘要 和现场口头报告，GFH375治疗NSCLC患者的最新研究结果预计将在今年国际学术会议发布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","BK4588","BK1161","159938","BK1574","BK1515","02595","BK4585","VXUS","09939"],"gpt_icon":0},{"id":"2617860476","title":"AI技术推动医药领域创新“加速跑”","url":"https://stock-news.laohu8.com/highlight/detail?id=2617860476","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617860476?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:27","pubTimestamp":1772789231,"startTime":"0","endTime":"0","summary":"AI成为2026年两会关注的热点，而随着AI技术的加速创新和应用，医药领域的新药研发也开启了“加速跑”。从底层技术突破到临床验证，一个由数据驱动、智能设计的医药研发新范式加速成型。近日，国内AI蛋白质设计公司分子之心，宣布其AI蛋白质优化与设计平台MoleculeOS完成重大升级，在抗体设计、酶改造等关键任务中达到解决实际产业难题的精度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603063664572449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","159938","BK1515","09939"],"gpt_icon":0},{"id":"2617683861","title":"3月6日美诺华涨8.41%，富安达医药创新混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617683861?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:23","pubTimestamp":1772785392,"startTime":"0","endTime":"0","summary":"证券之星消息，3月6日美诺华涨8.41%，收盘报22.31元，换手率7.17%，成交量15.49万手，成交额3.43亿元。重仓美诺华的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为富安达基金的富安达医药创新混合A。富安达医药创新混合A目前规模为0.8亿元，最新净值0.5545，较上一交易日上涨1.09%，近一年上涨2.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600025657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","BK1515","BK1161","09939","BK1574","603538"],"gpt_icon":0},{"id":"2617250977","title":"港股异动 | 同源康医药-B(02410)涨超5% 公司完成H股全流通 艾多替尼上市申请获正式受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2617250977","media":"智通财经网","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617250977?lang=zh_cn&edition=full","pubTime":"2026-03-06 11:55","pubTimestamp":1772769322,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B涨超5%，截至发稿，涨4.92%，报11.34港元，成交额2758.77万港元。消息面上，3月4日，同源康医药-B发布公告，本公司董事会欣然宣布，460.8万股非上市股份已于2026年3月4日完成转换为H股，该等经转换H股将于2026年3月5日上午九时正开始于联交所上市。近期，同源康医药-B宣布，其自主研发的针对非小细胞肺癌脑转移的甲磺酸艾多替尼片新药上市申请已获得中国国家药品监督管理局药品审评中心正式受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02410","VXUS","09939","BK1161","159938","BK4588","BK1574","BK4585","BK1515","VT"],"gpt_icon":0},{"id":"2617505805","title":"中银港股通医药混合发起A基金经理变动：增聘王方舟为基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2617505805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617505805?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:31","pubTimestamp":1772760661,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年3月6日，中银港股通医药混合发起发布公告，增聘王方舟为基金经理，任职日期自2026年3月6日起，变更后中银港股通医药混合发起的基金经理为王方舟,郑宁。截止2026年3月5日，中银港股通医药混合发起净值为1.4939，较上一日上涨2.33%，近一年上涨41.25%。王方舟先生：中国国籍，研究生、硕士，2017年加入中银基金管理有限公司，曾任研究员、基金经理助理。2025年12月23日起担任中银健康生活混合型证券投资基金的基金经理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600008014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1574","09939","159938","BK1161"],"gpt_icon":0},{"id":"2617919503","title":"【券商聚焦】交银国际：医药公司业绩兑现有望催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2617919503","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617919503?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:08","pubTimestamp":1772759313,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业周报，2026年以来，内资通过港股通持有医药股的比例呈现先降后升态势，当前水平与年初持平，外资持仓则有所提升。本周内资继续加仓创新药产业链和器械标的，外资则重点布局创新药企及CXO企业。年报季临近，本周各公司业绩预告陆续发布，该机构建议持续关注财务表现超预期、盈利路径清晰的公司，其业绩兑现有望催化板块行情。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976027","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516571.SGD","01099","02196","09688","LU0348735423.USD","LU1115378108.SGD","06160","BK1585","LU0561508036.HKD","IE00BPRC5H50.USD","LU2476274720.SGD","LU0348766576.USD","SG9999014674.SGD","SG9999004311.SGD","BK1207","BK1574","09939","BK1191","LU2399975544.HKD","LU0348827113.USD","LU1770034418.SGD","LU2328871848.SGD","BK1197","BK1515","LU0540923850.HKD","BK1141","03329","HK0000165453.HKD","LU2778985437.USD","LU1961090484.USD","02367","IE00B5MMRT66.SGD","LU2488822045.USD","159938","LU0588546209.SGD","BK1593","LU1794554557.SGD","01530","02268","LU1303224171.USD","02228","03933","LU2476274308.USD","LU0640798160.USD","09926","01789","LU0348783233.USD","LU1719994722.HKD","LU0348825331.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2617567493","title":"德琪医药新药授权给优时比；司美格鲁肽治疗MASH拟纳入优先审评｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2617567493","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617567493?lang=zh_cn&edition=full","pubTime":"2026-03-05 07:09","pubTimestamp":1772665768,"startTime":"0","endTime":"0","summary":"丨2026年3月5日星期四丨NO.1德琪医药CD19/CD3双抗新药授权给优时比德琪医药与优时比（UCB）联合宣布，双方已签署协议，德琪医药将授予优时比在全球范围内推进CD19/CD3双特异性T细胞连接抗体ATG-201的开发、生产及商业化的独家权益，并包括与ATG-201相关的生产技术授权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603053662203576.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603053662203576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159938","BK1161","06996","BK1515","BK1583","BK1191","09939"],"gpt_icon":0},{"id":"2617540575","title":"34岁潮汕籍女掌门，拿下100亿医药大单","url":"https://stock-news.laohu8.com/highlight/detail?id=2617540575","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617540575?lang=zh_cn&edition=full","pubTime":"2026-03-05 00:04","pubTimestamp":1772640248,"startTime":"0","endTime":"0","summary":"泰国富豪家族的医药生意，迎来重大突破。3月4日，中国生物制药的掌舵人谢其润签发公告，与全球制药巨头赛诺菲，就一款全球首创的移植领域药物，达成独家授权协议。这笔交易的总价为15.3亿美元，折合人民币超105亿元。谢其润团队将获得1.35亿美元的首付款。未来，基于潜在开发、监管和销售情况，她有望获得最高13.95亿美元的里程碑付款，以及最高双位数的销售分成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603053662120098.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603053662120098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","159938","BK1574","BK1515","09939"],"gpt_icon":0},{"id":"2616535244","title":"放弃百万年薪去读佛学！国联民生证券医药首席分析师郑薇离任：人生是随机盲盒，想做点真正想做的事","url":"https://stock-news.laohu8.com/highlight/detail?id=2616535244","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616535244?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:31","pubTimestamp":1772616660,"startTime":"0","endTime":"0","summary":"近日，国联民生证券股份有限公司研究所所长助理、医药首席分析郑薇正式告别证券研究行业，其下一站并非传统的买方或实业，而是香港大学文学院的佛学硕士课程。这位曾多次荣获金麒麟、新财富等奖项的分析师，用一封真诚的告别信，为自己的职业生涯画上了一个充满禅意的逗号。 2017年起，郑薇先后在华泰证券、天风证券（维权）任职，并于2017年至2021年担任天风证券医药首席分析师。在行业评选中，郑薇屡获殊荣。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-03-04/doc-inhpviht3959072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","BK1161","BK1564","159938","BK0276","601456","BK1515","BK1574","BK1147","01456","09939"],"gpt_icon":0},{"id":"2616538954","title":"3月4日常山药业跌5.88%，医药LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616538954","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616538954?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:46","pubTimestamp":1772613985,"startTime":"0","endTime":"0","summary":"证券之星消息，3月4日常山药业跌5.88%创60日新低，收盘报41.9元，换手率2.73%，成交量25.03万手，成交额10.64亿元。重仓常山药业的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的医药LOF。医药LOF目前规模为6.54亿元，最新净值0.5427，较上一交易日下跌2.09%，近一年上涨1.42%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/04/20260304142482.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/04/20260304142482.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260304/32044382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0172","BK1161","300255","BK0070","09939","BK1515","BK0239","159938","BK1574"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773215821121,"stockEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":-0.0242},{"period":"3month","weight":-0.0344},{"period":"6month","weight":-0.1387},{"period":"1year","weight":0.0487},{"period":"ytd","weight":-0.0046}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":0.0142},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.064},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医药,159938,医药股票,医药股票老虎,医药股票老虎国际,医药行情,医药股票行情,医药股价,医药股市,医药股票价格,医药股票交易,医药股票购买,医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}